The product line includes vaccines, monoclonal antibodies, and antigens.
In response to continued spread of monkeypox, Sanyou Biopharmaceuticals announced that it is launching a comprehensive line of monkeypox-targeting products.1 This includes vaccines, treatments, and antigens.
According to a press release, Sanyou is producing 65 items as part of this line. This includes 26 different antigens, 28 monoclonal antibody treatments, and 11 overexpression cell lines. These treatments should be effective against a variety of monkeypox strains.
Some of these treatments were developed using Sanyou’s antibody discovery platform. Earlier this month, Sanyou announced that it had officially launched its Innovative Intelligent Antibody Design oneClick+ Platform.2 The platform allows users to create antibody sequences, which then generates antibody reports.
In a press release issued at the time, Sanyou Bio’s CEO Dr. Guojun Lang said, “With the rapid development of intelligent technology, the intelligent construction of biologic drugs has become an inevitable path for industry development. It has also become a powerful engine for improving customer experience, simplifying business processes, and optimizing operational efficiency. The launch of the 'oneClick+' platform marks a significant step forward for Sanyou Bio in the field of intelligent antibody design. The convenience it offers will completely revolutionize the way users approach antibody design. We believe that the launch of the 'oneClick+' platform will provide our customers with an unprecedented experience and contribute to the intelligent development of the biopharmaceutical industry. Let us look forward to a brighter and better future for biologic drugs with the support of intelligent technology!"
Sanyou also announced this month that it had partnered with JiAnTeBo Biotechnology to jointly develop new agonist antibody drugs.3
In a press release issued at the time, JiAnTeBo founder professor Yin Zhinan said, “We will always be committed to finding innovative therapies in the field of metabolic diseases such as obesity, diabetes, fatty liver, and Alzheimer's disease. By partnering with Sanyou Bio, we will leverage their expertise technology and innovation capabilities in the field of antibodies and based on our existing protein pipeline and mRNA new drug pipeline, to accelerate the layout of our original research pipeline and promote the development of agonist antibody drugs, thus bringing more effective treatment options to patients suffering major diseases around the world."
In the same press release, Goujun added, “We are thrilled to partner on R&D with JiAnTeBo, an excellent team dedicated to pioneering innovative therapies. With Sanyou Bio's three major innovative drug R&D technology platforms: 'Super-Trillion, Integration, Intelligence,' we are confident in our ability to better assist JiAnTeBo in completing the strategic layout of innovative biological drugs. The strong alliance of the two parties will definitely bring new hope to more tumor and metabolic patients."
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
FDA Grants Priority Review to GSK’s Gepotidacin for Uncomplicated Urinary Tract Infections
October 18th 2024Priority Review status for GSK’s New Drug Application for gepotidacin was based on promising results from the Phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin in uncomplicated urinary tract infections.